Details

Fragment-based design of targeted covalent inhibitors : the scope and limitation of linking approaches
ID Kollár, Levente (Author), ID Mihalovits, Levente M. (Author), ID Bajusz, Dávid (Author), ID Knez, Damijan (Author), ID Simon, József (Author), ID Balcomb, Blake H. (Author), ID Fearon, Daren (Author), ID Gobec, Stanislav (Author), ID Keserü M., György (Author)

.pdfPDF - Presentation file, Download (5,48 MB)
MD5: 4C5400440AEBD306FFBBC72477C0870F
URLURL - Source URL, Visit https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202501108 This link opens in a new window

Abstract
Linking of fragments in neighboring binding sites is one of the optimization strategies in fragment-based drug discovery, where additive or even more substantial bioactivity improvements can be realized. However, such efforts present a considerable challenge when one fragment binds covalently to the target protein, as small modifications can influence the correct positioning of the covalent warhead toward the targeted nucleophilic residue. Here, we present a case study of fragment linking that yielded single-digit micromolar, covalent inhibitors of the SARS-CoV-2 main protease, starting from fragments that were inactive in the biochemical assay. Using structural information from a recent, high-throughput crystallographic fragment screen, we show that the success of fragment linking in the design of targeted covalent inhibitors is heavily impacted by several factors, including the warhead type, the labeling chemistry, and even subtle changes in the designed linker. Notably, we observe that induced fit effects might override the original fragment orientations in the linked molecule, highlighting the need for reliable structure verification, especially in consecutive rounds of fragment elaboration.

Language:English
Keywords:3CLpro inhibitors, covalent inhibitors, fragment linking, fragment-based drug discovery
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2026
Number of pages:Str. 1-16
Numbering:Vol. 21, iss. 10, art. e202501108
PID:20.500.12556/RUL-185268 This link opens in a new window
UDC:616.98-036.21:578.834
ISSN on article:1860-7187
DOI:10.1002/cmdc.202501108 This link opens in a new window
COBISS.SI-ID:281555459 This link opens in a new window
Publication date in RUL:30.07.2026
Views:253
Downloads:159
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:ChemMedChem
Shortened title:ChemMedChem
Publisher:Wiley-VCH-Verl..
ISSN:1860-7187
COBISS.SI-ID:519053337 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:zaviralci 3CLpro, kovalentni zaviralci, povezovanje fragmentov, odkrivanje zdravil na osnovi fragmentov, SARS-CoV-2, farmacevtska kemija

Projects

Funder:Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Project number:FK146063

Funder:Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Project number:SNN135335

Funder:Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Project number:2020-1.1.2-PIACI-KFI-2020-00039

Funder:Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Project number:RRF-2.3.1-21-2022-00015

Funder:Hungarian Academy of Sciences (NAP3.0) and Slovenian Research and Innovation Agency - ARIS
Project number:BI-HU/21-22-003

Funder:Other - Other funder or multiple funders
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back